
    no participants were enrolled. therefore, we stop this study, prematurely.
  
['hepatocellular carcinoma', 'lung metastasis']
['5-fluorouracil', 'mitomycin']

        Inclusion Criteria:

          -  Patients who have received previous local therapy treatments for the intrahepatic
             hepatocellular carcinoma (RFA, PEI, cryoablation, surgery, resection) and who don't
             have any viable intrahepatic tumor within 3 months of imaging (dynamic liver CT or
             liver MRI) after the locoregional therapy

          -  Patients who have measurable lung metastasis

          -  Patients who have received their last dose of sorafenib more than 14 days before and
             who had progressive disease of lung metastasis with sorafenib

          -  Patients who have risk factors of hepatocellular carcinoma (chronic hepatitis B,
             chronic hepatitis C, liver cirrhosis)

          -  Age : 18 years to 80 years

          -  ECOG Performance Status of 0 to 2

          -  Child-Pugh class A,B (Child-Pugh score 5-9)

          -  Adequate bone marrow, liver function as assessed by the following laboratory
             requirements to be conducted within 7 days prior to screening:

               -  WBC count > 1,000/mm3

               -  Absolute neutrophil count > 500/mm3

               -  Hb > 7.0 g/dL

               -  Platelet count > 50,000 /mm3

               -  Bilirubin < 3 mg/dL

               -  Adequate clotting function: INR < 2.3 or < 6sec

        Exclusion Criteria:

          -  Child-Pugh score > 10

          -  ECOG Performance Status > 3

          -  History of organ allograft

          -  Patients with uncontrolled co-morbidity which needs treatment

          -  Patients who have received prior systemic chemotherapy except sorafenib
      